摘要
目的探讨DC-CIK细胞联合手术治疗高龄原发性肝癌的疗效及对患者免疫功能的影响。方法将86例高龄原发性肝癌患者随机分成对照组和观察组,各43例。对照组接受肝癌切除手术,观察组在接受肝癌切除手术后同时应用DC-CIK细胞治疗。结果观察组总有效率为93.02%(40/43),高于对照组总有效率76.74%(33/43),差异具有统计学意义(P<0.05)。治疗后,原发性肝癌患者的CD3+、CD4+、CD4+/CD8+水平观察组高于对照组;且原发性肝癌患者CD8+水平观察组低于对照组,差异具有统计学意义(P<0.01)。治疗后,EORTCQLQ-C30评分系统各维度的评分观察组均高于对照组,差异具有统计学意义(P<0.01)。观察组患者的1年生存率为93.0%,高于对照组患者1年生存率76.7%;且观察组患者肿瘤复发率为2.3%,低于对照组患者肿瘤复发率18.6%,差异具有统计学意义(P<0.05)。结论 DC-CIK细胞联合手术治疗高龄原发性肝癌疗效显著,能够提高患者的免疫抵抗力,改善术后患者的生活质量,同时有助于延长患者的生存时间、降低肿瘤的复发。
Objective To explore DC-CIK cells combined surgical treatment for elderly patients with primary liver cancer and effect on immune function. Methods 86 cases of elderly patients with primary liver cancer were randomly divided into the control group and the observation group,43 cases in each. The control group received hepatectomy,and the observation group received DC-CIK cells after hepatectomy. Results The total effective rate in the observation group was 93. 02%( 40 /43),which was higher than that of the control group 76. 74%( 33 /43). the difference was statistically significant( P < 0. 05). After treatment,CD3 +,CD4 +,CD4 + / CD8 + levels in the observation group was higher than those of the control group,and CD8 + levels in the observation group was lower than that of the control group,the difference was statistically significant( P < 0. 01). After treatment,each dimension of EORTCQLQ-C30 scoring system in the observation group was higher than that of the control group,the difference was statistically significant( P < 0. 01). 1-year survival rate in the observation group was 93. 0%,which was higher than that of the control group 76. 7%,and tumor recurrence in the observation group was 2. 3%,which was less than that of the control group 18. 6%,the difference was statistically significant( P < 0. 05). Conclusion DC-CIK cells combined with surgical treatment for elderly patients with primary liver cancer has significant effect,it can improve immune resistance,and quality of life of patients,as well as increase the survival time and reduce tumor recurrence.
出处
《实用癌症杂志》
2015年第5期654-657,共4页
The Practical Journal of Cancer
